LP-284

Lantern Pharma reported Q3 2024 financial results and clinical updates, including an 86% clinical benefit rate in the LP-300 Harmonic™ Trial's initial cohort, expansion to Japan and Taiwan, and ongoing Phase 1 trials for LP-184 and LP-284 with no dose-limiting toxicities. LP-184 received FDA Fast Track Designation for Glioblastoma. Financial highlights include $28.1 million in cash and equivalents, R&D expenses of $3.7 million, and a net loss of $4.5 million ($0.42 per share). The company maintains three active clinical trials and advances AI-guided precision-oncology drug candidates.

Lantern Pharma to host two October webinars highlighting RADR® AI platform's role in advancing cancer therapies, including collaborations with Actuate Therapeutics and discussions on drug candidates LP-184 and LP-284.

Mantle cell lymphoma (MCL) treatment outcomes improve with novel targeted therapies like BTK inhibitors. DelveInsight's 'Mantle Cell Lymphoma Pipeline Insight 2024' covers 20+ companies developing 22+ therapies, including Venetoclax and ADI-001. Key events include AstraZeneca's Phase III ECHO trial and BeiGene's AACR presentation.